

US008961947B2

(12) United States Patent

Rehor et al.

(10) **Patent No.:**

US 8,961,947 B2

(45) **Date of Patent:**

Feb. 24, 2015

(54) POLYMERIC TISSUE SEALANT

75) Inventors: **Annemie Rehor**, Winterthur (CH);

Simona Cerritelli, Zurich (CH)

(73) Assignee: Kuros Biosurgery AG (CH)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 1568 days.

(21) Appl. No.: 12/102,157

(22) Filed: Apr. 14, 2008

(65) **Prior Publication Data**

US 2008/0253987 A1 Oct. 16, 2008

Related U.S. Application Data

(60) Provisional application No. 60/911,737, filed on Apr. 13, 2007.

(51)	Int. Cl.	
	A61K 31/74	(2006.01)
	A61L 31/06	(2006.01)
	A61L 24/04	(2006.01)
	C08G 65/332	(2006.01)
	C08G 65/333	(2006.01)
		(Continued)

(52) U.S. Cl.

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

3,908,039 A 9/1975 Guthrie et al.

4,008,341 A 2/1977 Kehr (Continued)

FOREIGN PATENT DOCUMENTS

CA 2281602 8/1998 EP 1 348 045 3/1974

(Continued)

OTHER PUBLICATIONS

Cellesi, F., et al., "Towars a fully-synthetic substitute . . . ", 2004, Biomaterials, 25, pp. 5115-5124.*

(Continued)

Primary Examiner — Paul Dickinson

(74) Attorney, Agent, or Firm — Pabst Patent Group LLP

(57) ABSTRACT

Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:

- i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2
- ii) the second precursor molecule is of the general formula: $A-[(C_3H_6O)_m-(C_2H_4O)_m-B]_i$

wherein m and n are integers from 1 to 200 i is greater than 2

A is a branch point

B is a conjugated unsaturated group

The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.

66 Claims, 4 Drawing Sheets

